Archive for September, 2008

« Older Entries
Newer Entries »

Vaccine Silly Season Heats Up: Vaccinate Children to Save Life Years!

Sunday, September 14th, 2008

The heat is on: against a growing background beat of “Pandemic’s nearly here, pandemic’s nearly here!” the repeated refrain of “Vet more vaccinations, get more shots!” is getting louder, too.

This time, we have a speculative paper that strikes me as absurd in which children are placed at high risk for getting vaccinated with yet more untested, potentially dangerous and very, very profitable vaccinations. In this case, the call is for saving the lives of children by vaccinating them with vaccines which contain deadly poisons like mercury, formaldehyde, fetal DNA, steal viruses, fluoride, chrolides, aluminum, etc., for a disease whose impact is vastly overstated (see “Flu Shot Does Not Reduce Risk of Death” following and not particularly the analysis of statistical conclusions about the death rate from flu. The highly absurd figure of 36,000 deaths per year from flu is used to sell flu vaccines and fear. But all, that’s right, all, deaths from pneumonia or any other possibly flu-related cause, whether it is or is not actually related to flu, is counted as a flu death in the grim sales pitch: get vaccinated or die.
As this second article cited shows, the reality, when examined closely, is nowhere near the puffery.
Well, what would you expect from a propaganda campaign?

Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org

Vaccinating Younger Population Minimizes Life-Years Lost to Influenza

NEW YORK (Reuters Health) Sept 05 – Shifting the current vaccination strategy to target younger populations would reduce the number of years of life lost (YLL) to influenza, according to a report in the August 1st issue of The Journal of Infectious Diseases.

Vaccination allocation policy has been the subject of debate in light of several issues, among them the criticism by bioethicists of the inherent axiom that any life lost has the same value, regardless of the age of the deceased, the authors explain.

Dr. Mark A. Miller from the National Institutes of Health, Bethesda, Maryland, and colleagues sought to provide an alternative quantitative tool to help guide pandemic vaccine priority setting and achieve the greatest possible population impact, by preventing the loss of as many years of life as possible.

For a 1918-like pandemic scenario, in which most YLL occur for the younger age groups, the optimal vaccination group comprises people younger than 45 years, according to the models employed.

For a 1957-like epidemic, in which YLL were similar for older and middle age groups, it is unclear whether vaccinating the middle-age group would be better than vaccinating seniors, leading the investigators to conclude “that these age groups would be equally good choices.”

For a mild 1968-like influenza epidemic, the researchers note, vaccinating people 45 to 64 years old represents the optimal strategy for minimizing YLL.

“Our estimation is not an endorsement of any particular policy but highlights how the choice of health outcome metrics such as YLL can influence the prioritization of age groups to vaccinate in pandemic settings,” the authors explain. “It also shows that the vaccine priority scheme for seasonal influenza is not optimized to mitigate the impact of pandemic influenza.”

“These results suggest the need for pandemic plans to have an element of flexibility that allows the prioritization of age groups for immunization at the start of a pandemic to be modified as age-specific epidemiological data on the novel virus become available in real time,” the researchers conclude.

“Equally important, the question of who should be vaccinated first needs to be debated and reasoned through now, before the onset of a public health emergency, while we have the time to reflect on which decision-making metric is the most appropriate,” they add.

J Infect Dis 2008;198:305-311.

Flu Shot Does Not Reduce Risk Of Death, Research Shows

ScienceDaily (Aug. 31, 2008) — The widely-held perception that the influenza vaccination reduces overall mortality risk in the elderly does not withstand careful scrutiny, according to researchers in Alberta. The vaccine does confer protection against specific strains of influenza, but its overall benefit appears to have been exaggerated by a number of observational studies that found a very large reduction in all-cause mortality among elderly patients who had been vaccinated.

The study included more than 700 matched elderly subjects, half of whom had taken the vaccine and half of whom had not. After controlling for a wealth of variables that were largely not considered or simply not available in previous studies that reported the mortality benefit, the researchers concluded that any such benefit “if present at all, was very small and statistically non-significant and may simply be a healthy-user artifact that they were unable to identify.”

“While such a reduction in all-cause mortality would have been impressive, these mortality benefits are likely implausible. Previous studies were likely measuring a benefit not directly attributable to the vaccine itself, but something specific to the individuals who were vaccinated—a healthy-user benefit or frailty bias,” said Dean T. Eurich,Ph.D. clinical epidemiologist and assistant professor at the School of Public Health at the University of Alberta. “Over the last two decades in the United Sates, even while vaccination rates among the elderly have increased from 15 to 65 percent, there has been no commensurate decrease in hospital admissions or all-cause mortality. Further, only about 10 percent of winter-time deaths in the United States are attributable to influenza, thus to suggest that the vaccine can reduce 50 percent of deaths from all causes is implausible in our opinion.”

Dr. Eurich and colleagues hypothesized that if the healthy-user effect was responsible for the mortality benefit associated with influenza vaccination seen in observational studies, there should also be a significant mortality benefit present during the “off-season”.

To determine whether the observed mortality benefits were actually an effect of the flu vaccine, therefore, they analyzed clinical data from records of all six hospitals in the Capital Health region in Alberta. In total, they analyzed data from 704 patients 65 years of age and older who were admitted to the hospital for community-acquired pneumonia during non-flu season, half of whom had been vaccinated, and half of whom had not. Each vaccinated patient was matched to a non-vaccinated patient with similar demographics, medical conditions, functional status, smoking status and current prescription medications.

In examining in-hospital mortality, they found that 12 percent of the patients died overall, with a median length of stay of approximately eight days. While analysis with a model similar to that employed by past observational studies indeed showed that patients who were vaccinated were about half as likely to die as unvaccinated patients, a finding consistent with other studies, they found a striking difference after adjusting for detailed clinical information, such as the need for an advanced directive, pneumococcal immunizations, socioeconomic status, as well as sex, smoking, functional status and severity of disease. Controlling for those variables reduced the relative risk of death to a statistically non-significant 19 percent.

http://www.sciencedaily.com/releases/2008/08/080829091323.htm

Tags:, , , , , , , , , , ,
Posted in Avian Flu, Compulsory Drugging, Disinformation, Medical Hazards, Miscellaneous, Privacy, Vaccination | No Comments »

Mainstream Medicine Getting There – Slowly: Zinc for Peds Diarrhea, Silver for Infection

Thursday, September 4th, 2008

There is good news making its way slowly, slowly into the medical world: little by little allopathic medicine is finally noticing how effective nutrients are in diseases and clinical conditions. Too slowly for most of us, but, still, there are creeping changes.
Instead of antibiotics, for example, pediatricians have noticed that pediatric diarrhea responds to zinc. Why? Because immune systems need zinc to do their job. So give the child zinc and it can fix the problem by itself without dangerous, expensive drugs. Well, well!
And even better, infection yields to silver. Well, of course it does. Burn centers have know that for decades and so has every natural doctor and naturopath for the last how many decades? But the derision and scorn heaped on us when we tried to talk about these and a thousand other ways of treating people when they come to us for cheap, simple, effective and safe means of getting well or staying that way is profound.
It is, however, the derision and anger born of fear.
Laibow’s First Law of Human Psychology is “Anger Drives Out Fear, Or At Least It’s Supposed To!” And conventional medicine is very, very afraid of the natural competitors to its expensive, dangerous and very limited drugs.
Oh, yes, one more thing: Codex Alimentarius makes the international trade of supplements very difficult since supplements may only be sold at doses so low that they have no clinical impact. Codex copmpliance in Europe through the European Food Supplements Directive is, in fact, stripping the shelves of stores of the nutrients previously avaialbe which might have allowed people to use the information in this article. Just ask any one you know, for example, in the UK, what is happening to their supplements: they are vanishing like the morning mist. Poof! Just like that.
If you don’t want the same thing to happen to you, it is imperative that you take action now, join the Natural Solutions Foundation’s distribution list for the free and secure Health Freedom eAlerts and take the action steps therein. I can assure you that legislators are not going to protect your health freedom without an effective outcry from us, the consumers who make our own choices about our own health paths.

Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org

Changes in Folate and Homocysteine Linked to Incident Dementia
http://www.medscape.com/viewarticle/579216?sssdmh=dm1.378114&src=nldne

NEW YORK (Reuters Health) Aug 18 – Onset of dementia is associated with decreasing folate and increasing vitamin B12 and homocysteine, results of a study published in the August issue of the Journal of Neurology, Neurosurgery, and Psychiatry indicate.

“Several cross-sectional studies have found significant associations of lower folate and hyperhomocysteinemia with dementia or cognitive impairment, but the direction of cause and effect is not known,” Dr. Jin-Sang Yoon, of University Medical School, Kwangiu, Republic of Korea, and colleagues write. “Results from prospective studies have been controversial.”

In their study, the researchers examined both baseline levels and changes in folate, vitamin B12, and homocysteine as predictors of incident dementia in 625 elderly patients free of dementia at baseline; 518 (83%) were followed over 2.4 years.

Incident dementia occurred in 45 of the 518 (8.7%). The only baseline factor that predicted incident dementia was lower folate concentrations

However, “The onset of dementia was significantly associated with an exaggerated decline in folate, a weaker increase in vitamin B12 concentrations and an exaggerated increase in homocysteine concentrations over the follow-up period,” the team reports.

After adjustment for weight change, these associations were reduced.

“Further research is required to clarify these complex longitudinal interrelationships,” Dr. Yoon and colleagues conclude. “In the meantime, attention needs to be paid to the nutritional status of people with dementia from the time of diagnosis onwards, regardless of whether this is a cause or effect of their condition.”

J Neurol Neurosurg Psychiatry 2008;79:864-868.Silver-Coated Endotracheal Tube Reduces Risk for Ventilator-Associated Pneumonia CME

News Author: Laurie Barclay, MD
CME Author: Penny Murata, MD
Disclosures
Release Date: August 19, 2008; Valid for credit through August 19, 2009
Credits Available

Physicians – maximum of 0.25 AMA PRA Category 1 Credit(s)â„¢ for physicians;
Family Physicians – up to 0.25 AAFP Prescribed credit(s) for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Learning Objectives

Upon completion of this activity, participants will be able to:

1. Compare the incidence of ventilator-associated pneumonia in patients intubated for at least 24 hours with a silver-coated endotracheal tube vs an uncoated endotracheal tube.
2. Report whether use of a silver-coated endotracheal tube affects duration of intubation, length of stay in the intensive care unit or hospital, mortality rates, and adverse events.

Authors and Disclosures

Laurie Barclay, MD
Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Penny Murata, MD
Disclosure: Penny Murata, MD, has disclosed no relevant financial relationships.

Brande Nicole Martin
Disclosure: Brande Nicole Martin has disclosed no relevant financial information.

August 19, 2008 — Use of a silver-coated endotracheal tube significantly reduces the incidence of microbiologically confirmed ventilator-associated pneumonia (VAP), according to the results of a large, randomized, multicenter study reported in the August 20 issue of the Journal of the American Medical Association.

“VAP causes substantial morbidity,” write Marin H. Kollef, MD, from the Washington University School of Medicine in St. Louis, Missouri, and colleagues from the North American Silver-Coated Endotracheal Tube Investigation Group. “A silver-coated endotracheal tube has been designed to reduce VAP incidence by preventing bacterial colonization and biofilm formation.”

The goal of this prospective, single-blind study conducted in 54 centers in North America was to evaluate whether use of a silver-coated endotracheal tube would reduce the incidence of microbiologically confirmed VAP.

Of 9417 adult patients aged 18 years or older who were screened between 2002 and 2006, a total of 2003 patients who were expected to need mechanical ventilation for at least 24 hours were randomly assigned to undergo intubation with 1 of 2 high-volume, low-pressure endotracheal tubes. These tubes were similar except that the experimental tube had a silver coating.

The main endpoint was incidence of VAP, diagnosed from quantitative bronchoalveolar lavage fluid culture with at least 104 colony-forming units/mL in patients intubated for at least 24 hours. Secondary endpoints were VAP incidence in all intubated patients, time to VAP onset, length of intubation and duration of intensive care unit and hospital stay, mortality rates, and adverse events.

Rates of microbiologically confirmed VAP in patients intubated for at least 24 hours were 4.8% (37/766 patients; 95% confidence interval [CI], 3.4% – 6.6%) in the group receiving the silver-coated tube and 7.5% (56/743; 95% CI, 5.7% – 9.7%; P = .03) in the group receiving the uncoated tube (relative risk reduction, 35.9%; 95% CI, 3.6% – 69.0%).

Rates of microbiologically confirmed VAP in all intubated patients were 3.8% (37/968; 95% CI, 2.7% – 5.2%) in the experimental group and 5.8% (56/964; 95% CI, 4.4% – 7.5%; P = .04) in the control group (relative risk reduction, 34.2%; 95% CI, 1.2% – 67.9%).

Use of the silver-coated endotracheal tube was associated with delayed occurrence of VAP (P = .005), but there were no statistically significant between-group differences in durations of intubation, intensive care unit stay, and hospital stay. Mortality rates and frequency and severity of adverse events were also similar in both groups.

“Patients receiving a silver-coated endotracheal tube had a statistically significant reduction in the incidence of VAP and delayed time to VAP occurrence compared with those receiving a similar, uncoated tube,” the study authors write. “The silver-coated endotracheal tube appears to offer a unique approach because it is the first intervention that becomes user-independent after intubation, requiring no further action by the clinician.”

Limitations of this study include single blinding rather than double blinding; use of a small, fixed block size stratified by center; other factors possibly contributing to between-group differences in VAP rates; study protocol not standardizing prevention strategies; and a protective effect of higher severity-of-illness scores against development of VAP.

In an accompanying editorial, Jean Chastre, MD, from Institut de Cardiologie, Groupe Hospitalier Pitié-Salpê trière in Paris, France, discusses the study limitations.

“Important uncertainties exist regarding the exact benefit of silver-coated endotracheal tubes,” Dr. Chastre writes. “Consequently, silver coated tubes should not be viewed as the definitive answer for VAP prevention, and, until additional data confirm the clinical effectiveness and cost benefit of these devices, their use should be restricted to high-risk patients treated in ICUs [intensive care units] with benchmark value-based infection rates that remain above institutional goals despite implementation of a comprehensive strategy of usual preventive measures to prevent VAP.”

CR Bard Inc supported this study and provided grant support to all of the study authors. Some of the study authors have disclosed various financial relationships with Kimberly Clark, Elan, Merck, Pfizer, Bayer, GlaxoSmithKline, Boehringer Ingelheim, KCI, sanofi-aventis, Johnson & Johnson, Easi, Hospira, Nomir Medical Technologies, Arpida, Cubist, Elan, Ortho-McNeil, Sanofi Pasteur, Wyeth, Bayer-Nektar, Nestle Clinical Nutrition, Lilly, Corbett Accel Healthcare, National Institutes of Health, Novartis, and/or Maquet. Dr. Chastre has received consulting and lecture fees from Pfizer, Brahms, Wyeth, Johnson & Johnson, Bayer-Nektar, and Arpida.

JAMA. 2008.300:805-813, 842-844.
Clinical Context

Rello and colleagues reported in the December 2002 issue of Chest that VAP is linked with increased morbidity rates and generally occurs in the first 10 days after endotracheal intubation. Probable causes of VAP include colonization with pathogenic bacteria and aspiration, as noted by Kollef in the June 2005 issue of Respiratory Care. In the November 2006 issue of Critical Care Medicine, Rello and colleagues found that a silver-coated endotracheal tube decreased bacterial colonization of the airway. The silver ions in a polymer on the inner and outer lumen migrate to the surface of the tube to potentially reduce bacterial adhesion, impede biofilm formation, and promote antimicrobial activity.

This prospective, randomized, controlled, multicenter, single-blind study assesses the efficacy of a silver-coated endotracheal tube in reducing the incidence of VAP in patients needing mechanical ventilation for at least 24 hours.
Study Highlights

* 2003 adults aged at least 18 years and expected to need at least 24 hours of mechanical ventilation were randomly assigned to use of a silver-coated endotracheal tube vs an uncoated endotracheal tube.
* Exclusion criteria were enrollment in a conflicting study, bronchiectasis, severe hemoptysis, cystic fibrosis, pregnancy, silver sensitivity, and more than 12 hours of endotracheal intubation in the previous 30 days.
* 1932 subjects were intubated: 968 in the silver-coated tube group and 964 in the uncoated tube group.
* 1509 subjects were intubated for at least 24 hours: 766 in the silver-coated tube group and 743 in the uncoated tube group.
* Baseline characteristics for both groups were similar for age (mean age, 60.9 – 62.2 years; range, 18 – 102 years), sex, Acute Physiology and Chronic Health Evaluation II score, immunocompetency, enteral nutrition use, and endotracheal tube size.
* Both groups had similar VAP risk factors, except chronic obstructive pulmonary disease was less common in the silver-coated tube group vs the uncoated tube group (24-hour intubation subjects, 11.6% vs 16.4%; P = .007; all intubated subjects, 9.2% vs 12.7%; P = .02).
* The primary outcome measure was VAP incidence, defined by at least 104 colony-forming units/mL in bronchoalveolar lavage fluid culture, in patients intubated for at least 24 hours.
* VAP incidence in patients intubated for at least 24 hours was lower in the silver-coated tube group vs the uncoated tube group (4.8% [37/766 patients] vs 7.5% [56/743 patients]; P = .03; relative risk reduction, 35.9%).
* VAP incidence in all intubated patients was lower in the silver-coated tube group vs the uncoated tube group (3.8% vs 5.8%; P = .04; relative risk reduction, 34.2%).
* Bronchoalveolar lavage fluid culture was also obtained in those with suspected VAP or with new radiographic infiltrate and at least 2 qualifying signs (fever or hypothermia, leukocytosis or leukopenia, or purulent tracheal aspirate).
* Of 220 patients who underwent bronchoalveolar lavage for suspected VAP, the most common pathogens for the silver-coated tube group vs the uncoated tube group were Staphylococcus aureus (9 vs 16), Pseudomonas aeruginosa (8 vs 11), Enterobacteriaceae (10 vs 5), and polymicrobial infections (7 vs 13).
* VAP incidence within 10 days of intubation in patients intubated for at least 24 hours was less common in the silver-coated tube group (relative risk reduction, 47.6%; 95% CI, 14.6% – 81.9%; P = .005).
* Delayed occurrence of VAP was linked to silver-coated tube use (P = .005).
* There was no difference between groups in median duration of intubation, intensive care unit stay, hospital stay, and mortality rates.
* Regression analysis showed that silver-coated tube use was associated with decreased risk for VAP at any time, VAP within 10 days of intubation, and delayed time to occurrence.
* Adverse events occurred with similar frequency and severity for both groups.
* 59 endotracheal tube–related adverse events occurred: 21 in the silver-coated tube group vs 38 in the uncoated tube group.
* 74 intubation procedure–related adverse events occurred: 39 in the silver-coated tube group vs 35 in the uncoated tube group.
* Post hoc analysis showed that VAP in patients intubated for at least 24 hours was linked with longer duration of intubation and longer length of stay in the intensive care unit or hospital but not with mortality rate.
* Limitations of the study included lower than expected VAP incidence in the uncoated tube group, more subjects with chronic obstructive pulmonary disease in the uncoated tube group, and lack of blinding of investigators.

Pearls for Practice

* The incidence of VAP in patients intubated for at least 24 hours is reduced and delayed with use of a silver-coated endotracheal tube vs an uncoated endotracheal tube.
* Use of a silver-coated endotracheal tube does not affect duration of intubation, length of stay in the intensive care unit or hospital, mortality rates, or adverse events.
http://www.medscape.com/viewarticle/579239?sssdmh=dm1.378114&src=nldne

Oral zinc for treating diarrhoea in children.

Cochrane Database Syst Rev. 2008; (3):CD005436 (ISSN: 1469-493X)

Lazzerini M; Ronfani L
Unit of Research on Health Services and International Health, WHO Collaborating Centre for Maternal and Child Health, Via dei Burlo 1,34123, Trieste, Italy.

BACKGROUND: Diarrhoea causes around two million child deaths annually. Zinc supplementation could help reduce the duration and severity of diarrhoea, and is recommended by the World Health Organization and UNICEF. OBJECTIVES: To evaluate oral zinc supplementation for treating children with acute or persistent diarrhoea. SEARCH STRATEGY: In November 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007, Issue 4), MEDLINE, EMBASE, LILACS, CINAHL, mRCT, and reference lists. We also contacted researchers. SELECTION CRITERIA: Randomized controlled trials comparing oral zinc supplementation (>/= 5 mg/day for any duration) with placebo in children aged one month to five years with acute or persistent diarrhoea, including dysentery. DATA COLLECTION AND ANALYSIS: Both authors assessed trial eligibility and methodological quality, extracted and analysed data, and drafted the review. Diarrhoea duration and severity were the primary outcomes. We summarized dichotomous outcomes using risk ratios (RR) and continuous outcomes using mean differences (MD) with 95% confidence intervals (CI). Where appropriate, we combined data in meta-analyses (using the fixed- or random-effects model) and assessed heterogeneity. MAIN RESULTS: Eighteen trials enrolling 6165 participants met our inclusion criteria. In acute diarrhoea, zinc resulted in a shorter diarrhoea duration (MD -12.27 h, 95% CI -23.02 to -1.52 h; 2741 children, 9 trials), and less diarrhoea at day three (RR 0.69, 95% CI 0.59 to 0.81; 1073 children, 2 trials), day five (RR 0.55, 95% CI 0.32 to 0.95; 346 children, 2 trials), and day seven (RR 0.71, 95% CI 0.52 to 0.98; 4087 children, 7 trials). The four trials (1458 children) that reported on diarrhoea severity used different units and time points, and the effect of zinc was less clear. Subgroup analyses by age (trials with only children aged less than six months) showed no benefit with zinc. Subgroup analyses by nutritional status, geographical region, background zinc deficiency, zinc type, and study setting did not affect the results’ significance. Zinc also reduced the duration of persistent diarrhoea (MD -15.84 h, 95% CI -25.43 to -6.24 h; 529 children, 5 trials). Few trials reported on severity, and results were inconsistent. No trial reported serious adverse events, but vomiting was more common in zinc-treated children with acute diarrhoea (RR 1.71, 95% 1.27 to 2.30; 4727 children, 8 trials). AUTHORS’ CONCLUSIONS: In areas where diarrhoea is an important cause of child mortality, research evidence shows zinc is clearly of benefit in children aged six months or more.
Subject Headings
Major Subject Heading(s) Minor Subject Heading(s)

* PreMedline Identifier: 18646129

Tags:, , , , , , , , , , , , , , ,
Posted in About Codex Alimentarius, CODEX Consequences, Dietary Supplements, Miscellaneous, Promising Developments, Psychiatric Drugs | No Comments »

How Much Is A Baby’s Life Worth in A Clinical Trial?

Thursday, September 4th, 2008

Big Pharma is all heart. Here is a striking example of its deep concern for our collective and individual well being: In New Delhi, 49 babies died in clinical trials in just 30 months. That’s one baby every 0.61 months, a little over half.
Did no one notice? Did no one want to give up the payments they were getting? How much as the premier All India Institute of Medicine getting per baby? Who was getting it?
How many of the responsible people will go to jail?
What do you learn in this type of trial from a baby? Or are they simply the most vulnerable and helpless group so they make great experimental subjects.
I have a lot more questions, and I bet you do, too.
But the answers that are clear are pretty grim. I am reminded of the Polish vagrants, more than 300 of them, who for $1 or $2 were injected with the Sanofi-Pasteur vaccine. That dollar cost many of them their lives and the doctors and nurses involved are on trial for murder (as is a sister company, Sanofi Aventis, for homicide because of the contaminated Hepatitis B Vaccine they were given.
The stories go on and on and on of Big Pharma and the Illness Care industry using us as their guinea pigs wth no regard for us and our well-being.
Be warned. The next time you hear that a vaccine or a pharmaceutical is good for you, ask if the pronoun is correct or if what you are really being told is “the Vaccine or pharmaceutical is good for ME, the doctor or the hospital or the Drug company.”
Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org

49 babies died during clinical trials at AIIMS
Sunday, August 17, 2008
New Delhi: As many as 49 babies have died during clinical trials at the premier All India Institute of Medical Sciences (AIIMS) during the last two-and-a-half years, the reply to a Right to Information (RTI) query has revealed.

The AIIMS paediatrics department conducted 42 sets of trials on 4,142 babies – 2,728 of them below the age of one – since Jan 1, 2006.

Forty-nine babies died during the trials. AIIMS says the deaths amounted to a 1.18 percent mortality rate, according to its reply to the RTI query.

“A total of 49 deaths corresponding to 1.18 percent mortality among the enrolled patients were recorded in the studies. These include deaths both in the control and intervention groups, as per the designs of individual studies,” the reply says.

The reasons for the babies’ deaths, their ages or their gender are not contained in the reply – since these were not specifically asked by the applicant, Rahul Verma, founder of NGO Uday Foundation for Congenital Defects and Rare Blood Groups.

Verma, in fact, had filed separate queries with the same set of questions with the paediatrics department and the paediatrics surgery department. He says he received an unsatisfactory reply from the latter and is going to file an appeal in the case.

Clinical trials are research studies that test how well new medical formulations work on people. Each study attempts to find better ways to prevent, screen for, diagnose, and treat a disease.

If carefully conducted, clinical trials are the safest and fastest way of finding treatments that work.

In reply to a query on who the five top funding agencies for the trials were, AIIMS named the institute itself, the Indian Council of Medical Research (ICMR), the Department of Biotechnology (DBT), the World Health Organisation (WHO) and the Johns Hopkins Bloomberg School of Public Health in the US.

Five foreign-manufactured medicines were tested during the trials. They were:

* Zinc tablets for treating Zinc deficiency and serving as a nutritional supplement,

* Olmesartan and Valsartan for treating blood pressure related problems,

* Rituximab for treating chronic focal encephalitis, a condition affecting the brain, and

* Gene-activated human glucocerebrosidase – for treating Gaucher disease that affects the liver.

In reply to another query, AIIMS said that before conducting the trials, it had taken clearance from its own Ethics Committee, the Health Ministry Steering Committee (HMSC) on ethics and the National Ethics Committees of ICMR and DBT.

Verma, however, maintained that there were legal and ethical lacunae in the system as permissions had to be sought from different agencies depending on the nature of the trials.
http://news.indiainfo.com/2008/08/17/0808171932_49_babies_died_during_clinical_trials_at_aiims_in_last_30_months.html

Tags:, , , , , ,
Posted in Compulsory Drugging, Disinformation, Hall of Shame, Medical Hazards, Miscellaneous | No Comments »

Avian Flu Deaths to Require Mass Graves in UK: 17 Week Delay Between Death and Burial Anticipated

Thursday, September 4th, 2008

Mass graves, a 17 week delay between death and burial, schools closed for 10 weeks while hundreds of thousands or even millions of people die in a 15 week nightmare in the UK.
Yes, a successful weaponised Avian Flu certainly can ruin your day unless you happen to be a One World Government Globalist with depopulation tendencies, of course.

Look at what the British Government is planning for and recall that there is not a single human case of Avian Flu, let alone a death, anywhere in Europe and then tell me that this makes sense. Because to me this sounds exactly like more Psy Ops – “Soften ’em up, get them used to the idea and make ’em really afraid. Then you can do whatever you want with them”
Well, not me and not you.
The more that we disseminate our skepticism and our accurate information, the harder the job of the fear mongers becomes.
Gullibility is their tool and their friend.
Knowledge is ours.
Please make sure that everyone you know signs up for the informative and important free and secure Health Freedom eAlert, http://www.healthfreedomusa.org/index.php?page_id=187. It’s free and its filled with information that we need to disseminate widely.
Speaking truth to power is our protection. We are the Power, after all.
Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org

London – Britain is considering mass human burials should a bird flu pandemic break out, The Sunday Times newspaper said.
A “prudent” worst-case assessment suggested 320 000 people could die in Britain if the H5N1 virus mutated into a form contagious to humans, according to a confidential Home Office report seen by the weekly.
Titled Managing Excess Deaths in an Influenza Pandemic and dated March 22, [2008] the document reportedly says that such a large number of deaths could lead to delays of up to 17 weeks in burying or cremating victims.
It warned that “common burial” would stir up images of the mass burial pits used during the Great Plague of 1665.
But in fact it “might involve a large number of coffins buried in the same place at the same time, in such a way that allowed for individual graves to be marked”.
The Sunday Times weekly said the report had been discussed last week in a cabinet subcommittee chaired by Health Secretary Patricia Hewitt.
Avian influenza is lethal to poultry and dangerous for humans in close proximity to infected fowl. It has claimed more than 100 lives, according to a World Health Organisation toll.
But, apart from a few anecdotal cases, the mortality has occurred exclusively by direct transmission from birds to humans and not among humans themselves. To acquire that contagiousness would open the way to a pandemic.
The report suggests that local authorities could cope with a “base case” of 48 000 deaths in England and Wales in a 15-week pandemic.
But it warned: “Even with ramping local management capacity by 100 percent, the prudent worst case of 320 000 excess deaths is projected to lead to a delay of some 17 weeks from death to burial or cremation.”
Should the outbreak kill 2.5% of those who contract the flu, it added, “no matter what emergency arrangements are put in place there are likely to be substantially more deaths than can be managed within current timescales”.
It said vaccines would not be available in the first wave of a pandemic, and possibly longer, and should not be seen as a “silver bullet”.
The report suggests schools would have to close for up to 10 weeks because children would be “super-spreaders” of bird flu.
The Home Office said it did not comment on leaked documents.
A spokesperson added: “The government is taking seriously the possible threat of an influenza pandemic in the light of the global situation and the possibility that a novel strain of the influenza virus could emerge.
“Prudent precautionary planning is under way across all elements of the response, including the health service, other essential services and local authorities.”
The H5N1 virus has been detected in nearby France.

Tags:, , , , ,
Posted in Avian Flu, Disinformation, Miscellaneous, Privacy, Vaccination | No Comments »

Mad Cow Madness at USDA

Thursday, September 4th, 2008

Irrational behavior, I have learned over many years as a psychiatrist, is usually meaningful and makes sense if you understand the underlying premise. Failing insanity, the underlying premise is usually a closely guarded secret. Once that secret is out in the open, the formerly irrational behavior makes sense.

So what is the secret at the USDA which makes it behave irrationally when a small meat packer wants to test each and every one of its cows to prove that its product, beef, is safe to eat? Why does the US Government, now backed up by its Court system, adamantly refuse to allow Creekstone Farms to assure its potential customers that its beef is safe and free of this devastating disease?

Could it be because there is so much Mad Cow disease in the rest of the American meet supply?
Read this astonishing and horrifying story below.
Yours in health and freedom,
Dr. Rima
Rima E. Laibow, MD
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMedia.tv
www.NaturalSolutionsMarketPlace.org


Court bars Meatpacker Tests for Mad Cow
By Charles Abbott
Fri Aug 29, 2008
WASHINGTON (Reuters) – The Agriculture Department is within bounds to bar meatpackers from testing slaughter cattle for mad cow disease, a U.S. Court of Appeals panel said in a 2-1 ruling on Friday.
Creekstone Farms Premium Beef LLC, a small Arkansas packer, filed suit on March 23, 2006, to gain access to mad-cow test kits. It said it wanted to test every animal at its plant to assure foreign buyers that the meat was safe to eat.
Three U.S. cases of mad cow disease, a fatal neurological infection, have been reported, the last in March 2006. People can contract a human version of the disease by eating infected meats. Most nations banned U.S. beef after the first case, in December 2003, but trade has been restored for the most part.
In a 25-page ruling, Appellate Judges Karen Henderson and Judith Rogers said USDA has authority under the 1913 Virus-Serum-Toxin Act to prevent sale of mad-cow test kits to meatpackers. USDA interprets the law to control products for “prevention, diagnosis, management or care of diseases of animals.”
David Sentelle, chief judge of the District of Columbia appeals circuit, dissented from the decision. He said USDA “exceeds the bounds of reasonableness” for a law enacted to prevent the sale of ineffective animal medicine.
USDA allows the mad-cow test kits to be sold only to laboratories that it approves. It says the tests should not be used as a marketing tool and the cattle that comprise the bulk of the meat supply are too young to be tested reliably.
Two large export markets, Japan and South Korea, accept beef only from younger U.S. cattle. Mad cow is found mostly in older cattle. Its incubation period is two to eight years.
Creekstone said it lost $200,000 a day due to reduced U.S. beef exports when it filed its lawsuit.
In its lawsuit, Creekstone argued the 1913 law could not be invoked to prevent use of products like “rapid test” kits for mad cow disease and the kits were not a “treatment” for livestock.
U.S. District Judge James Robinson had ruled in March 2007 that USDA could not control mad cow tests because they are not a treatment for animals.
The United States applies a number of safeguards against mad cow, formally named bovine spongiform encephalopathy. They include a ban on using cattle parts in feed and requirements for packers to remove at slaughter the materials most likely to carry the mad-cow agent — the brain, spinal column and nervous system tissue.
(Editing by Walter Bagley)
http://www.reuters.com/article/email/idUSN2928450820080829?pageNumber=1&virtualBrandChannel=10003

Tags:, , ,
Posted in Medical Hazards, Miscellaneous, Privacy | No Comments »

« Older Entries
Newer Entries »